Expression of cancer/testis antigens in prostate cancer is associated with disease progression.

Takahito Suyama, Takumi Shiraishi, Y. Zeng, Wei Yu, Nehal Parekh, Robert L. Vessella, Jun Luo, Robert H. Getzenberg, Prakash Kulkarni

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The cancer/testis antigens (CTAs) are a unique group of proteins normally expressed in germ cells but aberrantly expressed in several types of cancers including prostate cancer (PCa). However, their role in PCa has not been fully explored. METHODS: CTA expression profiling in PCa samples and cell lines was done utilizing a custom microarray that contained probes for two-thirds of all CTAs. The data were validated by quantitative PCR (Q-PCR). Functional studies were carried out by silencing gene expression with siRNA. DNA methylation was determined by methylation-specific PCR. RESULTS: A majority of CTAs expressed in PCa are located on the X chromosome (CT-X antigens). Several CT-X antigens from the MAGEA/CSAG subfamilies are coordinately upregulated in castrate-resistant prostate cancer (CRPC) but not in primary PCa. In contrast, PAGE4 is highly upregulated in primary PCa but is virtually silent in CRPC. Further, there was good correlation between the extent of promoter DNA methylation and CTA expression. Finally, silencing the expression of MAGEA2 the most highly upregulated member, significantly impaired proliferation of prostate cancer cells while increasing their chemosensitivity. CONCLUSIONS: Considered together, the remarkable stage-specific expression patterns of the CT-X antigens strongly suggests that these CTAs may serve as unique biomarkers that could potentially be used to distinguish men with aggressive disease who need treatment from men with indolent disease not requiring immediate intervention. The data also suggest that the CT-X antigens may be novel therapeutic targets for CRPC for which there are currently no effective therapeutics.

Original languageEnglish (US)
Pages (from-to)1778-1787
Number of pages10
JournalProstate
Volume70
Issue number16
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

Testicular Neoplasms
Disease Progression
Prostatic Neoplasms
Antigens
DNA Methylation
Polymerase Chain Reaction
X Chromosome
Germ Cells
Methylation
Small Interfering RNA
Therapeutics
Biomarkers
Gene Expression
Cell Line

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Suyama, T., Shiraishi, T., Zeng, Y., Yu, W., Parekh, N., Vessella, R. L., ... Kulkarni, P. (2010). Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate, 70(16), 1778-1787.

Expression of cancer/testis antigens in prostate cancer is associated with disease progression. / Suyama, Takahito; Shiraishi, Takumi; Zeng, Y.; Yu, Wei; Parekh, Nehal; Vessella, Robert L.; Luo, Jun; Getzenberg, Robert H.; Kulkarni, Prakash.

In: Prostate, Vol. 70, No. 16, 01.12.2010, p. 1778-1787.

Research output: Contribution to journalArticle

Suyama, T, Shiraishi, T, Zeng, Y, Yu, W, Parekh, N, Vessella, RL, Luo, J, Getzenberg, RH & Kulkarni, P 2010, 'Expression of cancer/testis antigens in prostate cancer is associated with disease progression.', Prostate, vol. 70, no. 16, pp. 1778-1787.
Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL et al. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate. 2010 Dec 1;70(16):1778-1787.
Suyama, Takahito ; Shiraishi, Takumi ; Zeng, Y. ; Yu, Wei ; Parekh, Nehal ; Vessella, Robert L. ; Luo, Jun ; Getzenberg, Robert H. ; Kulkarni, Prakash. / Expression of cancer/testis antigens in prostate cancer is associated with disease progression. In: Prostate. 2010 ; Vol. 70, No. 16. pp. 1778-1787.
@article{5bffcbcce8e047bb923810ec982acf77,
title = "Expression of cancer/testis antigens in prostate cancer is associated with disease progression.",
abstract = "BACKGROUND: The cancer/testis antigens (CTAs) are a unique group of proteins normally expressed in germ cells but aberrantly expressed in several types of cancers including prostate cancer (PCa). However, their role in PCa has not been fully explored. METHODS: CTA expression profiling in PCa samples and cell lines was done utilizing a custom microarray that contained probes for two-thirds of all CTAs. The data were validated by quantitative PCR (Q-PCR). Functional studies were carried out by silencing gene expression with siRNA. DNA methylation was determined by methylation-specific PCR. RESULTS: A majority of CTAs expressed in PCa are located on the X chromosome (CT-X antigens). Several CT-X antigens from the MAGEA/CSAG subfamilies are coordinately upregulated in castrate-resistant prostate cancer (CRPC) but not in primary PCa. In contrast, PAGE4 is highly upregulated in primary PCa but is virtually silent in CRPC. Further, there was good correlation between the extent of promoter DNA methylation and CTA expression. Finally, silencing the expression of MAGEA2 the most highly upregulated member, significantly impaired proliferation of prostate cancer cells while increasing their chemosensitivity. CONCLUSIONS: Considered together, the remarkable stage-specific expression patterns of the CT-X antigens strongly suggests that these CTAs may serve as unique biomarkers that could potentially be used to distinguish men with aggressive disease who need treatment from men with indolent disease not requiring immediate intervention. The data also suggest that the CT-X antigens may be novel therapeutic targets for CRPC for which there are currently no effective therapeutics.",
author = "Takahito Suyama and Takumi Shiraishi and Y. Zeng and Wei Yu and Nehal Parekh and Vessella, {Robert L.} and Jun Luo and Getzenberg, {Robert H.} and Prakash Kulkarni",
year = "2010",
month = "12",
day = "1",
language = "English (US)",
volume = "70",
pages = "1778--1787",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "16",

}

TY - JOUR

T1 - Expression of cancer/testis antigens in prostate cancer is associated with disease progression.

AU - Suyama, Takahito

AU - Shiraishi, Takumi

AU - Zeng, Y.

AU - Yu, Wei

AU - Parekh, Nehal

AU - Vessella, Robert L.

AU - Luo, Jun

AU - Getzenberg, Robert H.

AU - Kulkarni, Prakash

PY - 2010/12/1

Y1 - 2010/12/1

N2 - BACKGROUND: The cancer/testis antigens (CTAs) are a unique group of proteins normally expressed in germ cells but aberrantly expressed in several types of cancers including prostate cancer (PCa). However, their role in PCa has not been fully explored. METHODS: CTA expression profiling in PCa samples and cell lines was done utilizing a custom microarray that contained probes for two-thirds of all CTAs. The data were validated by quantitative PCR (Q-PCR). Functional studies were carried out by silencing gene expression with siRNA. DNA methylation was determined by methylation-specific PCR. RESULTS: A majority of CTAs expressed in PCa are located on the X chromosome (CT-X antigens). Several CT-X antigens from the MAGEA/CSAG subfamilies are coordinately upregulated in castrate-resistant prostate cancer (CRPC) but not in primary PCa. In contrast, PAGE4 is highly upregulated in primary PCa but is virtually silent in CRPC. Further, there was good correlation between the extent of promoter DNA methylation and CTA expression. Finally, silencing the expression of MAGEA2 the most highly upregulated member, significantly impaired proliferation of prostate cancer cells while increasing their chemosensitivity. CONCLUSIONS: Considered together, the remarkable stage-specific expression patterns of the CT-X antigens strongly suggests that these CTAs may serve as unique biomarkers that could potentially be used to distinguish men with aggressive disease who need treatment from men with indolent disease not requiring immediate intervention. The data also suggest that the CT-X antigens may be novel therapeutic targets for CRPC for which there are currently no effective therapeutics.

AB - BACKGROUND: The cancer/testis antigens (CTAs) are a unique group of proteins normally expressed in germ cells but aberrantly expressed in several types of cancers including prostate cancer (PCa). However, their role in PCa has not been fully explored. METHODS: CTA expression profiling in PCa samples and cell lines was done utilizing a custom microarray that contained probes for two-thirds of all CTAs. The data were validated by quantitative PCR (Q-PCR). Functional studies were carried out by silencing gene expression with siRNA. DNA methylation was determined by methylation-specific PCR. RESULTS: A majority of CTAs expressed in PCa are located on the X chromosome (CT-X antigens). Several CT-X antigens from the MAGEA/CSAG subfamilies are coordinately upregulated in castrate-resistant prostate cancer (CRPC) but not in primary PCa. In contrast, PAGE4 is highly upregulated in primary PCa but is virtually silent in CRPC. Further, there was good correlation between the extent of promoter DNA methylation and CTA expression. Finally, silencing the expression of MAGEA2 the most highly upregulated member, significantly impaired proliferation of prostate cancer cells while increasing their chemosensitivity. CONCLUSIONS: Considered together, the remarkable stage-specific expression patterns of the CT-X antigens strongly suggests that these CTAs may serve as unique biomarkers that could potentially be used to distinguish men with aggressive disease who need treatment from men with indolent disease not requiring immediate intervention. The data also suggest that the CT-X antigens may be novel therapeutic targets for CRPC for which there are currently no effective therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=78349240805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349240805&partnerID=8YFLogxK

M3 - Article

C2 - 20583133

AN - SCOPUS:78349240805

VL - 70

SP - 1778

EP - 1787

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 16

ER -